Small molecule inhibitors
Small-molecule inhibitors are low-molecular-weight compounds designed or identified to reduce the activity of a biological target, commonly by occupying a catalytic site, an allosteric pocket, or a protein–protein interaction interface.
Small-molecule inhibitors are low-molecular-weight compounds designed or identified to reduce the activity of a biological target, commonly by occupying a catalytic site, an allosteric pocket, or a protein–protein interaction interface. Their effects may include suppression of enzyme catalysis, disruption of signaling pathways, or alteration of protein conformational dynamics. Unlike biologic therapies such as monoclonal antibodies, small molecules can provide chemically tunable mechanisms of action and are investigated across diverse therapeutic areas, including Cancer, inflammatory disease, infectious disease, and neurodegenerative disorders.
The entity represents a therapeutic strategy rather than a single compound or drug. Current research includes inhibitors of phospholipase A2 (PLA2) and other snake-venom activities, the KAT6A acetyltransferase, the SARS-CoV-2 Nsp3 Mac1 macrodomain, GDNF-associated inflammatory signaling, PD-L1 (CD274), and TNFR1. These studies use approaches including co-crystal structures, molecular dynamics simulation, machine learning, molecular modelling, and fragment-based drug discovery. In cancer, small-molecule inhibitors are also being investigated alongside cisplatin, (chemo)radiotherapy, nanocarriers, and immune-targeting strategies involving PD-1/PD-L1. Their development remains constrained by challenges such as target selectivity, limited structural information, and therapeutic resistance.
Where the papers sit
9 papers from the last 6 months study small molecule inhibitors directly · updated from PubMed 15 Nov 2026
Study type 0 clinical trials · 1 observational · 5 human data · 3 preclinical
Themes one subject
Those 9 are all about one subject.
-
Broad Inhibitor Discovery
Early inhibitor discovery spans glioblastoma signaling, viral macrodomains, TNFR1, PD-L1, KAT6A and GDNF. Structural biology, fragment screening and computational modelling recur, alongside nanomedicine studies in colorectal cancer. The biological aims range from antiviral activity and immunomodulation to cancer therapy and venom-related inflammation. No single therapeutic direction or shared mechanism unifies the group.
Papers
The 9 papers from the last 6 months that study small molecule inhibitors directly, newest first, by theme and by study type. Study types come from PubMed publication types and MeSH headings.
By theme
Broad Inhibitor Discovery (9)
- Adaptive kinase signaling enables escape from small molecule inhibition in glioblastoma. Cancer biology & therapy · 3 Nov 2026 PMID 42975206
- Why does local edema persist? Immunological mismatch between phospholipase A2 potency and antivenom affinity in Protobothrops mucrosquamatus envenomation. PLoS neglected tropical diseases · 3 Sept 2026 PMID 42691029
- KAT6A-inhibitor co-crystal structures: tackling a challenging crystallization target via two alternative approaches. Acta crystallographica. Section D, Structural biology · 27 Aug 2026 PMID 42657771
- Discovery of thiobarbiturate-indole scaffold as a selective inhibitor targeting chikungunya virus nsP3 macrodomain through a cryptic binding pocket. European journal of medicinal chemistry · 30 Jul 2026 PMID 42531898
- X-ray Crystallography-Guided Design and Synthesis of Cyclopentyl Heteroaryl Carboxylic Acid-Based Inhibitors of the SARS-CoV-2 Nsp3 Macrodomain (Mac1). Journal of medicinal chemistry · 13 Jul 2026 PMID 42439527
- Discovery of Ligands for the TNFR1 Extracellular Domain Using Fragment-Based Drug Discovery. ChemMedChem · 3 Jul 2026 PMID 42399717
- Nanomedicine-Based Therapeutic Approaches in Colorectal Cancer Using Patient-Derived Xenograft Models: Prospects and Challenges. International journal of nanomedicine · 18 Jun 2026 PMID 42311426
- Computational discovery and molecular modelling of small-molecule modulators of GDNF. Biochemical and biophysical research communications · 4 Jun 2026 PMID 42241930
- In silico discovery of novel small-molecule PD-L1 inhibitors through a multi-stage computational workflow integrating machine learning and molecular dynamics. Journal of computer-aided molecular design · 25 May 2026 PMID 42185552
By study type
Observational studies and case reports (1)
- Why does local edema persist? Immunological mismatch between phospholipase A2 potency and antivenom affinity in Protobothrops mucrosquamatus envenomation. PLoS neglected tropical diseases · 3 Sept 2026 PMID 42691029
Human data, design not indexed (5)
- KAT6A-inhibitor co-crystal structures: tackling a challenging crystallization target via two alternative approaches. Acta crystallographica. Section D, Structural biology · 27 Aug 2026 PMID 42657771
- X-ray Crystallography-Guided Design and Synthesis of Cyclopentyl Heteroaryl Carboxylic Acid-Based Inhibitors of the SARS-CoV-2 Nsp3 Macrodomain (Mac1). Journal of medicinal chemistry · 13 Jul 2026 PMID 42439527
- Discovery of Ligands for the TNFR1 Extracellular Domain Using Fragment-Based Drug Discovery. ChemMedChem · 3 Jul 2026 PMID 42399717
- Computational discovery and molecular modelling of small-molecule modulators of GDNF. Biochemical and biophysical research communications · 4 Jun 2026 PMID 42241930
- In silico discovery of novel small-molecule PD-L1 inhibitors through a multi-stage computational workflow integrating machine learning and molecular dynamics. Journal of computer-aided molecular design · 25 May 2026 PMID 42185552
Preclinical: animal, cell and lab studies (3)
- Adaptive kinase signaling enables escape from small molecule inhibition in glioblastoma. Cancer biology & therapy · 3 Nov 2026 PMID 42975206
- Discovery of thiobarbiturate-indole scaffold as a selective inhibitor targeting chikungunya virus nsP3 macrodomain through a cryptic binding pocket. European journal of medicinal chemistry · 30 Jul 2026 PMID 42531898
- Nanomedicine-Based Therapeutic Approaches in Colorectal Cancer Using Patient-Derived Xenograft Models: Prospects and Challenges. International journal of nanomedicine · 18 Jun 2026 PMID 42311426
Written from 9 PubMed abstracts, each one listed by PMID above. Published: 2026-09-05. Drafted by language models from published abstracts; not medical advice.